Ad-hoc | 28 June 2006 08:57
STRATEC concludes major agreement for design of next generation instrumentation
Ad hoc announcement transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
STRATEC concludes major agreement for design of next generation
instrumentation
Birkenfeld, June 28, 2006
STRATEC Biomedical Systems AG (SIN: 728900 / ISIN: DE0007289001) today
announced the conclusion of an exclusive agreement to develop fully
automated instrumentation for one of the key players acting worldwide
successfully in the field of molecular diagnostics.
STRATEC’s partner will make an up-front payment followed by additional
payments based on STRATEC’s achievement of product development milestones.
Initial payments under the agreement will total less than USD 2 million,
about 20 – 25% of the overall development payments to STRATEC.
The analyzer system is conceived as our partner’s next generation molecular
diagnostics platform intended to automate their current and future
portfolio of proprietary DNA and RNA testing systems for Screening,
Monitoring and Diagnosis.
The parties have agreed to begin to negotiate the modalities for the
manufacture and supply of the analyzer system in an early phase of the
development project, which is scheduled to span a period of about three
years.
—————————————————————————
Information and Explaination of the Issuer to this News:
Hermann Leistner, STRATEC’s founder and Chief Executive Officer, commented,
‘This agreement is another major milestone in STRATEC’s company history as
it allows us to draw on our expertise in the development of instrumentation
for molecular diagnostic applications – the fastest growing segment of the
diagnostics market.’
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories and research
institutes around the world. The company develops its products on the basis
of its own patented technologies. Shares in the company (SIN: 728900 /
ISIN: DE0007289001) are traded in the Prime Standard segment of the
Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart
Stock Exchange and on other exchanges.
The STRATEC Group comprises the listed holding company ‘STRATEC Biomedical
Systems AG’, as well as the subsidiaries ‘STRATEC NewGen’, ‘Robion’ and
‘Sanguin’.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
E-Mail: ir@stratec-biomedical.de
(c)DGAP 28.06.2006
—————————————————————————
Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
WWW: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin-Bremen, München, Düsseldorf
End of News DGAP News-Service
—————————————————————————